A Moderna and Merck personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% compared to standard treatment.
Back to Lifestyle
Lifestyle
October 22, 2026 at 7:03 PM
STAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial
STAT News
Excerpt from STAT News.
